Education
About Us
Working with TipRanks
Follow Us
Biorestorative Therapies, Inc. (BRTX)
:BRTX
BRTX Stock Chart & Stats
$1.62
-$0.13(-7.22%)
At close: 4:00 PM EST
$1.62
-$0.13(-7.22%)
Day’s Range― - ―
52-Week Range$1.19 - $2.55
Previous CloseN/A
Volume34.37K
Average Volume (3M)228.79K
Market Cap
$11.95M
Enterprise ValueN/A
Total Cash (Recent Filing)$7.38M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Mar 26, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding8,656,242
10 Day Avg. Volume37,485
30 Day Avg. Volume228,790
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.30
Price to Sales (P/S)27.69
P/FCF Ratio-1.33
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market ExpansionBRTX-100 has received IND clearance to move into a Phase 2 study for cervical spinal pain, potentially expanding its market and application.
Product DifferentiationHypoxic culturing makes BRTX-100 differentiated in cell therapy, offering a unique advantage in the market.
Regulatory ApprovalThe company recently received Fast Track designation from FDA, which could expedite the approval process for its treatments.
Bears Say
Clinical Trial EnrollmentBioRestorative has made further progress with enrollment passing the 1/3rd mark.
BioRestorative Therapies News
BRTX FAQ
What was Biorestorative Therapies, Inc.’s price range in the past 12 months?
Biorestorative Therapies, Inc. lowest stock price was $1.19 and its highest was $2.55 in the past 12 months.
What is Biorestorative Therapies, Inc.’s market cap?
Biorestorative Therapies, Inc.’s market cap is $11.95M.
When is Biorestorative Therapies, Inc.’s upcoming earnings report date?
Biorestorative Therapies, Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 132 days.
How were Biorestorative Therapies, Inc.’s earnings last quarter?
Biorestorative Therapies, Inc. released its earnings results on Nov 12, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.36 by $0.03.
Is Biorestorative Therapies, Inc. overvalued?
According to Wall Street analysts Biorestorative Therapies, Inc.’s price is currently Overvalued.
Does Biorestorative Therapies, Inc. pay dividends?
Biorestorative Therapies, Inc. does not currently pay dividends.
What is Biorestorative Therapies, Inc.’s EPS estimate?
Biorestorative Therapies, Inc.’s EPS estimate is -0.34.
How many shares outstanding does Biorestorative Therapies, Inc. have?
Biorestorative Therapies, Inc. has 8,656,242 shares outstanding.
What happened to Biorestorative Therapies, Inc.’s price movement after its last earnings report?
Biorestorative Therapies, Inc. reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.36. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Biorestorative Therapies, Inc.?
Currently, no hedge funds are holding shares in BRTX
Company Description
Biorestorative Therapies, Inc.
BioRestorative Therapies (BRTX) is a biotechnology company focused on the development of innovative therapeutic solutions using cell and tissue therapies. The company operates primarily in the field of regenerative medicine, with a particular emphasis on stem cell-based therapies for the treatment of chronic lumbar disc disease and metabolic disorders. Its core products include BRTX-100, a stem cell-based therapeutic targeting disc/spine disease, and ThermoStem, a program focused on metabolic disorders including obesity and diabetes.
BRTX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant milestones in the company's clinical and commercial development, such as the Fast Track designation for BRTX-100 and a new patent for ThermoStem. However, these were counterbalanced by a sharp revenue decline and increased net loss compared to the previous year. Despite the financial setbacks, the overall sentiment is cautiously optimistic with strategic developments and a strengthened financial position.View all BRTX earnings summariesTechnical Analysis
Cellectar Biosciences
―
Marker Therapeutics
―
Cocrystal Pharma
―
Sensei Biotherapeutics
―
AEON Biopharma
―
Ownership Overview
14.69% Insiders
0.96% Mutual Funds
1.17% Other Institutional Investors
82.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---